国际肿瘤学杂志››2021,Vol. 48››Issue (12): 762-763.doi:10.3760/cma.j.cn371439-20201224-00152
郝志强, 朱巍(
)
收稿日期:2020-12-24修回日期:2021-02-18出版日期:2021-12-08发布日期:2022-01-12通讯作者:朱巍 E-mail:18686111667@163.com
Received:2020-12-24Revised:2021-02-18Online:2021-12-08Published:2022-01-12摘要：
Krukenberg瘤是一种罕见肿瘤,恶性程度高,目前治疗方式以姑息性手术联合化疗为主。现报道1例应用卡瑞利珠单抗免疫治疗Krukenberg瘤患者,该患者卵巢癌术后病理示Krukenberg瘤,进一步检查证实来源于胃体部低分化腺癌,因化疗耐受性差,结合PD-L1检测结果选择卡瑞利珠单抗免疫治疗,患者治疗1年余,病情控制理想,耐受性好。
郝志强, 朱巍. 卡瑞利珠单抗维持治疗Krukenberg瘤一例[J]. 国际肿瘤学杂志, 2021, 48(12): 762-763.
图1
1例Krukenberg瘤患者胃镜活检病理图片 HE染色 ×200"
图2
1例Krukenberg瘤患者胃镜活检免疫组织化学PD-L1表达图片 SP法 ×400 注:PD-L1为程序性死亡受体配体-1"
图3
1例Krukenberg瘤患者胃镜活检病理HER-2扩增情况图片 FISH检测 ×1 000 注:HER-2为人表皮生长因子受体-2"
| [1] | Man M, Cazacu M, Oniu T. Krukenberg tumors of gastric origin versus Krukenberg tumors of colorectal origin[J]. Chirurgia(Bucur), 2007,102(4):407-410. |
| [2] | Kim HK, Heo DS, Bang YJ, et al. Prognostic factors of Krukenberg's tumor[J]. Gynecol Oncol, 2001,82(1):105-109. DOI: 10.1006/gyno.2001.6210. |
| [3] | Tran PN, Sarkissian S, Chao J, et al. PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence[J]. Gastrointest Cancer, 2017,7:1-11. DOI: 10.2147/GICTT.S113525. |
| [4] | Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial[J]. JAMA Oncol, 2020,6(10):1571-1580. DOI: 10.1001/jamaoncol.2020.3370. |
| [5] | Shitara K, Özgüro$\check{g}$lu M, Bang YJ, et al. Pembolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial [J]. Lancet, 2018,392(10142):123-133. DOI: 10.1016/S0140-6736(18)31257-1. |
| [6] | Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017,390(10111):2461-2471. DOI: 10.1016/S0140-6736(17)31827-5. |
| [7] | Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial[J]. JAMA Oncol, 2018, 4(5): e180013. DOI 10.1001/jamaoncol.2018.0013. |
| [8] | Xu J, Zhang Y, Jia R, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study[J]. Clin Cancer Res, 2019,25(2):515-523. DOI: 10.1158/1078-0432.CCR-18-2484. |
| [9] | Huang J, Mo H, Zhang W, et al. Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China[J]. Cancer, 2019,125(5):742-749. DOI: 10.1002/cncr.31855. |
| [1] | 杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337. |
| [2] | 许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363. |
| [3] | 严爱婷, 王翠竹, 刘春桂, 鲁小敏.卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142. |
| [4] | 吕璐, 孙鹏飞.肠道菌群与宫颈癌[J]. 国际肿瘤学杂志, 2023, 50(6): 373-376. |
| [5] | 黄华玉, 龚虹云, 宋启斌.胸部放疗联合免疫治疗时代肺炎发生的影响因素[J]. 国际肿瘤学杂志, 2023, 50(2): 102-106. |
| [6] | 张雨潇, 张连生, 李莉娟.新型免疫检查点TIGIT在多发性骨髓瘤免疫治疗中的研究现状与应用前景[J]. 国际肿瘤学杂志, 2023, 50(2): 122-125. |
| [7] | 张碧霞, 丁江华.EGFR突变型非小细胞肺癌EGFR-TKI获得性耐药后免疫治疗现状[J]. 国际肿瘤学杂志, 2023, 50(2): 97-101. |
| [8] | 陈文莉, 倪志华, 陈红宇, 畅立圣, 范德生, 刘立伟, 丁青薇.免疫联合靶向治疗恶性腹膜间皮瘤1例[J]. 国际肿瘤学杂志, 2022, 49(8): 509-512. |
| [9] | 唐琳, 相明月, 张建波, 王丽丽, 巩合义, 韩大力.卡瑞利珠单抗联合阿帕替尼及化疗二线或以上治疗HER-2阴性晚期胃癌的临床疗效及安全性[J]. 国际肿瘤学杂志, 2022, 49(5): 276-281. |
| [10] | 孙笑可, 杨宇.肝细胞癌基因组及转录组特征与免疫相关性[J]. 国际肿瘤学杂志, 2022, 49(5): 302-306. |
| [11] | 黄华玉, 宋启斌, 龚虹云, 宋佳.接受胸部放疗和免疫治疗肺癌患者肺炎发生率及影响因素分析[J]. 国际肿瘤学杂志, 2022, 49(12): 718-723. |
| [12] | 李瑛珏, 路丹.PI3K通路在肿瘤免疫微环境中的作用机制[J]. 国际肿瘤学杂志, 2022, 49(11): 677-680. |
| [13] | 徐秋月, 马咸梅, 岳琦.基于分子分型的子宫内膜癌免疫治疗[J]. 国际肿瘤学杂志, 2022, 49(11): 700-704. |
| [14] | 林先勇, 胡翔, 殷海涛.免疫治疗联合放化疗治疗非小细胞肺癌的临床研究进展[J]. 国际肿瘤学杂志, 2022, 49(1): 56-60. |
| [15] | 安江宏, 钱莘, 骆璞, 谭晓华.肠道微生态与肿瘤的诊断和治疗[J]. 国际肿瘤学杂志, 2021, 48(7): 436-440. |
| 阅读次数 | ||||||
| 全文 |
|
|||||
| 摘要 |
|
|||||
